Art

J-GLOBAL ID：201602239075616772   Reference number：16A1220690

Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors

変異体選択的なアロステリック阻害剤によってEGFR(T790M),EGFR(C797S)による薬剤耐性を克服する

Author (29)： JIA Yong (Genomics Inst. of the Novartis Res. Foundation, California, USA) ,  MANUIA Mari (Genomics Inst. of the Novartis Res. Foundation, California, USA) ,  JUAREZ Jose (Genomics Inst. of the Novartis Res. Foundation, California, USA) ,  LELAIS Gerald (Genomics Inst. of the Novartis Res. Foundation, California, USA) ,  DIDONATO Michael (Genomics Inst. of the Novartis Res. Foundation, California, USA) ,  BURSULAYA Badry (Genomics Inst. of the Novartis Res. Foundation, California, USA) ,  MICHELLYS Pierre-Yves (Genomics Inst. of the Novartis Res. Foundation, California, USA) ,  EPPLE Robert (Genomics Inst. of the Novartis Res. Foundation, California, USA) ,  MARSILJE Thomas H. (Genomics Inst. of the Novartis Res. Foundation, California, USA) ,  MCNEILL Matthew (Genomics Inst. of the Novartis Res. Foundation, California, USA) ,  LU Wenshuo (Genomics Inst. of the Novartis Res. Foundation, California, USA) ,  HARRIS Jennifer (Genomics Inst. of the Novartis Res. Foundation, California, USA) ,  BENDER Steven (Genomics Inst. of the Novartis Res. Foundation, California, USA) ,  YUN Cai-Hong (Dana-Farber Cancer Inst., Massachusetts, USA) ,  PARK Eunyoung (Dana-Farber Cancer Inst., Massachusetts, USA) ,  JANG Jaebong (Dana-Farber Cancer Inst., Massachusetts, USA) ,  ECK Michael J. (Dana-Farber Cancer Inst., Massachusetts, USA) ,  YUN Cai-Hong (Harvard Medical School, Massachusetts, USA) ,  PARK Eunyoung (Harvard Medical School, Massachusetts, USA) ,  JANG Jaebong (Harvard Medical School, Massachusetts, USA) ,  ECK Michael J. (Harvard Medical School, Massachusetts, USA) ,  ERCAN Dalia (Dana-Farber Cancer Inst., Massachusetts, USA) ,  XU Chunxiao (Dana-Farber Cancer Inst., Massachusetts, USA) ,  RHEE Kevin (Dana-Farber Cancer Inst., Massachusetts, USA) ,  CHEN Ting (Dana-Farber Cancer Inst., Massachusetts, USA) ,  ZHANG Haikuo (Dana-Farber Cancer Inst., Massachusetts, USA) ,  WONG Kwok-Kin (Dana-Farber Cancer Inst., Massachusetts, USA) ,  JAENNE Pasi A. (Dana-Farber Cancer Inst., Massachusetts, USA) ,  PALAKURTHI Sangeetha (Dana-Farber Cancer Inst., Massachusetts, USA)
Material： Nature (London)  (Nature (Lond))
Volume： 534  Issue： 7605  Page： 129-132  Publication year： Jun. 02, 2016 
JST Material Number： D0193B  ISSN： 0028-0836  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Thesaurus term： allosteric effect ,  EGF receptor ,  *drug resistance ,  *mutant ,  selection ,  *antitumor drug ,  *enzyme inhibitor ,  *molecular targeting drug ,  tyrosine kinase ,  *non-small cell lung cancer ,  binding site ,  genetic variation ,  *gene ,  covalent bond ,  action mechanism ,  targeting ,  crystal structure ,  steric conformation ,  biochemical analysis ,  monoclonal antibody ,  biological preparation ,  mouse(animal)
Semi thesaurus term： allosteric inhibition ,  variant selection ,  *tyrosine kinase inhibitor ,  *receptor gene ,  Treatment target ,  Cetuximab

JST classification (3)： Experimental treatment for tumors  (GE02040Y) ,  Tumors(=neoplasms)of respiratory system  (GI04000G) ,  Basic research of antitumor(=antineoplastic)drugs  (GW16010A)

Substance index (3)： Gefitinib ,  Erlotinib ,  Afatinib

Terms in the title (3)： 変異体選択 ,  EGFR ,  薬剤耐性